By: Nitesh Sinha, Sandeep Kumar, Anuj Jain, Rajesh Chandra, Harish Kumar
Objectives: High-flow nasal cannula (HFNC) therapy is a first-line respiratory support modality for acute hypoxemic respiratory failure (AHRF) due to COVID-19 pneumonia. The respiratory rate-oxygenation (ROX) index, defined as the ratio of peripheral oxygen saturation (SpO












